Background-β-Blockers exert a prognostic benefit in the treatment of chronic heart failure. Their pharmacological properties vary. The only substantial comparative trial to date-the Carvedilol or Metoprolol European Trial-has compared carvedilol with short-acting metoprolol tartrate at different dose equivalents. We therefore addressed the relative efficacy of equal doses of carvedilol and metoprolol succinate on survival in multicenter hospital outpatients with chronic heart failure. Methods and Results-Four thousand sixteen patients with stable systolic chronic heart failure who were using either carvedilol or metoprolol succinate were identified in the Norwegian Heart Failure Registry and The Heart Failure Registry of the University of Heidelberg, Germany. Patients were individually matched on both the dose equivalents and the respective propensity scores for β-blocker treatment. During a follow-up for 17 672 patient-years, it was found that 304 (27.2%) patients died in the carvedilol group and 1066 (36.8%) in the metoprolol group. In a univariable analysis of the general sample, metoprolol therapy was associated with higher mortality compared with carvedilol therapy (hazard ratio, 1.49; 95% confidence interval, 1.31-1.69; P<0.001). This difference was not seen after multivariable adjustment (hazard ratio, 0.93; 95% confidence interval, 0.57-1.50; P=0.75) and adjustment for propensity score and dose equivalents (hazard ratio, 1.06; 95% confidence interval, 0.94-1.20; P=0.36) or in the propensity and dose equivalent-matched sample (hazard ratio, 1.00; 95% confidence interval, 0.82-1.23; P=0.99). These results were essentially unchanged for all prespecified subgroups. Conclusions-In outpatients with chronic heart failure, no conclusive association between all-cause mortality and treatment with carvedilol or metoprolol succinate was observed after either multivariable adjustment or multilevel propensity score matching. (Circ Heart Fail. 2015;8:887-896.
T he beneficial effects of β-blockers are well established in chronic heart failure (CHF) patients with reduced ejection fraction. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] This is confirmed by a class 1A indication in all relevant guidelines. [12] [13] [14] The optimal selection of a particular β-blocker, however, is under debate. Because the available agents differ in their selectivity for adrenergic receptors and their effects on peripheral circulation, there is controversy whether β-blockers exert a class effect or whether 1 β-blocker is superior to another. [15] [16] [17] To date, limited trial data are available on the comparative effectiveness of β-blockers in CHF. [18] [19] [20] [21] The largest prospective randomized clinical trial that directly compared the efficacy of 2 β-blockers is the Carvedilol or Metoprolol European Trial study 10 was 200 mg once daily-as recommended by all CHF guidelines. Carvedilol, however, was dosed at full guideline target dose in COMET.
In addition, real-life patients with CHF differ from patients included in randomized trials. Differences in baseline blood pressure and other factors may further influence physician's selection of a certain β-blocker. We therefore compared the effect of equivalent doses of carvedilol and long-acting metoprolol succinate on survival in a multicenter real-world cohort of patients with stable systolic CHF from 2 countries.
Methods Databases
Patients' data were extracted from the Norwegian Heart Failure Registry and the heart failure outpatients' clinic of the University of Heidelberg, Germany. Recruitment was prospective and continuous for each database and center. All patients gave their written informed consent for data storage and evaluation. The study conformed to the principles outlined in the Declaration of Helsinki and was approved by the Regional Committee for Medical and Health Research Ethics and the Norwegian Data Inspectorate for the Norwegian Heart Failure Registry and the Ethics Committee of Heidelberg for the Heidelberg Heart Failure Registry.
The Norwegian Heart Failure Registry was initiated in October 2000, and patients were enrolled from outpatients' clinics of 27 recruiting hospitals well distributed in all regions of Norway, ranging in size and scope from small community to large university hospitals. The participating centers recorded their data using a web-based database.
Patients who attended the specialized outpatients' heart failure clinic of the University of Heidelberg, Germany, for evaluation of HF were offered inclusion into the local HF registry. Less than 1% of patients refused to participate. Because the Heidelberg University Hospital has been serving as a primary healthcare center as well as a tertiary referral center for the Rhein-Neckar region, the registry reflects a broad representation of patients of that region.
All participating hospitals in both the countries had cardiologists responsible for the heart failure clinics, which were managed by specially trained nurses working closely with these cardiologists.
Patient Selection and Follow-Up
Both the databases reflect an all-comers cohort. All patients were included after stabilization of both clinical status and medication. Patients were enrolled into the Norwegian Heart Failure Registry between April 2000 and February 2013, whereas inclusion into the Heart Failure Registry of the University of Heidelberg was performed between August 1996 and December 2012. To be eligible for this study, patients had to (1) attend the heart failure outpatients' clinic of any of the participating hospitals, (2) provide written informed consent for inclusion into the heart failure registry, (3) have a history of systolic heart failure, and (4) be treated with either carvedilol or metoprolol succinate in conjunction with either an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker. β-Blocker treatment was initiated before inclusion of patients in the study in all cases, and stability of dosing for at least 6 weeks was verified from the patient's or respective general physician's history or electronic hospital records. Medication was at the discretion of the referring physician.
The diagnosis of heart failure was established according to guidelines on the basis of typical symptoms and signs resulting from an objective abnormality of cardiac structure or function on echocardiography, cardiac magnetic resonance imaging, or left heart catheterization. 14 All included patients had a left ventricular ejection fraction (LVEF) <45%.
Baseline characteristics included medical history, physical examination, LVEF, laboratory results, and medication. Glomerular filtration rate was estimated using the Modification of Diet in Renal Disease equation.
Surviving patients were followed up for a minimum of 6 months. Determination of survival status and follow-up were performed by scheduled visits to the outpatient clinic, by telephone calls either to the patients' homes or to their physicians, or by electronic hospital records. For the purpose of this analysis, patients alive at this point were censored as alive at the date of this last contact. In addition, for the Norwegian Heart Failure Registry, mortality data were obtained at regular intervals from the National Statistics Bureau, Statistics Norway. All-cause mortality was the predefined end point for the purpose of this analysis.
Statistical Analysis
All tests are 2-tailed, and P<5% was regarded as statistically significant. Variables are presented as mean±SD, median (interquartile range), or number percentages (%) as appropriate. Chi-squared test was performed to compare frequencies. To test the significant differences between groups, the 2-sample Wilcoxon signed-rank test and Student t test were used where appropriate. Differences in event-free survival were analyzed using uni-and multivariable Cox proportional hazard models and displayed using the Kaplan-Meier plot for survival.
To account for possible confounders, 3 strategies were applied: First, all variables found to be significant in univariable Cox analysis and those different between β-blocker groups were entered in a single multivariable Cox model. Second, a propensity score for the conditional probability of receiving either β-blocker (carvedilol versus metoprolol succinate) was derived as described below and used together with β-blocker equivalent dose for control in a common (trivariable) model. Third, a 2-level matching process was performed as described below, and the original analysis was repeated in the matched cohort.
Because our database includes patients from 28 hospitals in 2 European countries, regional differences may affect study results. To account for a possible center-related bias, multivariable analyses included individual center as a forced independent covariate.
Subgroups
Analyses were repeated in prespecified subgroups with respect to age (above versus below median), sex, cause of heart failure (ischemic versus nonischemic), LVEF (≤35% versus >35%), NYHA functional class (I/II versus III/IV), renal function (glomerular filtration rate, ≤60 mL/min per 1.73 m² versus >60 mL/min per 1.73 m²), obstructive pulmonary disease (yes versus no), diabetes mellitus (yes versus no), heart rate (≤75 versus >75 per minute), rhythm (sinus rhythm, yes versus no), and blood pressure (above versus below median). In addition, survival was analyzed in patients with sinus rhythm plus LVEF ≤35% because this patient cohort showed the greatest benefit from carvedilol therapy in COMET. Interaction terms were calculated for each of the predefined subgroups in the propensity-matched sample.
Propensity Score and Matching
The propensity score was calculated as the single composite variable from a nonparsimonious multivariate logit-linked binary logistic regression of the baseline characteristics. The β-blocker agent was a dependent variable. 22 The logit of the probability of receiving either carvedilol or metoprolol succinate according to this score formed the basis of our matching procedure. Dose equivalent of the respective β-blocker was not part of the propensity score to separately account for one of the main criticisms of the COMET trial.
Patients were individually matched on both the propensity of receiving either β-blocker and their dose equivalents using the Mayo Clinic SAS macro gmatch. The matching procedure was performed in 2 steps. First, caliper matching of the propensity score was applied with caliper size predefined as 0.2 of the SD of the total sample. 23 In a 1-pass procedure starting with a given patient receiving carvedilol, the closest match of a patient receiving metoprolol succinate was identified. Second, dose equivalents for the β-blockers were compared. If doses were equivalent or varied ≤10%, the pair of patients was retained for analysis and removed from the total sample to allow for the next matching cycle to take place. If doses were varied >10%, the pair was rejected. Then the first step of the matching process was repeated to identify the next closest match to the carvedilol patient of the failed match according to the propensity score. If a further patient on metoprolol succinate was thus identified, the second step was repeated. In case of no match according to the propensity score and dose equivalent could be identified, the carvedilol patient was removed from the total sample and the matching cycle started with the next patient receiving carvedilol.
Bias Reduction, Balance, and Sensitivity Analysis
Balance of baseline covariates before and after matching was assessed using standardized differences 24, 25 and the efficacy of discrimination of the model using C-statistic. In addition, we conducted a formal sensitivity analysis to quantify the degree of a hidden bias that would need to be present to invalidate our main conclusions 26 following the method suggested by Love. 27 To check for covariates that are related to the treatment but not to the outcome (instrumental variables), we ran univariable logistic regressions on treatment followed by cox regressions on outcome with all variables that were included in the multivariable model. Those variables that were related to treatment and not to outcome were further analyzed by running 2-variable cox regressions of that variable and additionally the treatment variable.
As missing values of variables may cause bias in the multivariable model because of list-wise deleting, we repeated the multivariable calculations by performing an available case analysis. Moreover, we performed a multiple imputation analysis with n=100 repetitions using the Markov chain Monte Carlo method. This procedure replaces each missing value with a set of plausible values that represent the uncertainty about the right value to impute. Then the multivariable calculations were repeated in the multiple imputed data set. Moreover, following the study by Mitras et al, 28 the calculation of the propensity score was repeated in each of the multiple imputed data sets. The propensity score was averaged for each record across the completed data sets. Then, the averaged propensity score was used along with the β-blocker dose equivalent to perform caliper matching. In line with the original propensity score matching, the caliper size was defined as 0.2× SD of the averaged propensity score, and the β-blocker dose equivalent varied ≤10%.
Results

Patient Characteristics and Follow-Up
We identified a total of 4016 patients who met the inclusion criteria outlined above. Of these, 3311 patients were extracted from the Norwegian Heart Failure Registry, and 705 patients were included into the Heart Failure Registry of the University of Heidelberg. The number of patients included in each participating center is shown in Table I (Table 1) . Overall, patients receiving metoprolol succinate were older and more likely to be NYHA functional class III than those on carvedilol. In addition, the proportion of patients with ischemic heart failure was higher in the metoprolol succinate group.
Total follow-up was 212 066 patient-months (17 672 patient-years) with a mean follow-up duration of 52.8±33.6 months. During that time, a total of 1370 patients (34.1%) died, 1066 (36.8%) in the metoprolol succinate group and 304 (27.2%) in the carvedilol group.
Prognostic Significance in the General Example
In a univariable analysis of the complete sample (n=4016), receipt of metoprolol succinate was associated with higher Figure 1 ). This result did not persist when controlling for the propensity of receiving the individual β-blocker and the β-blocker equivalent dose in a trivariable model using these variables (HR, 
Subgroups (General Sample)
Subgroup analyses in the general sample with respect to age, sex, cause of heart failure, LVEF, NYHA functional class, renal function, obstructive pulmonary disease, diabetes mellitus, heart rate, rhythm, blood pressure, and sinus rhythm plus LVEF ≤35% for both controlling strategies mainly confirmed nonsuperiority of either β-blocker. The few significant results were inconsistent between adjustment strategies. Although the trivariable (propensity score/β-blocker equivalent dose-adjusted) models found metoprolol succinate to be associated with higher all-cause mortality in younger patients, in nondiabetics, in patients with ischemic cause, in patients with a heart rate ≤75 per minute, in patients with sinus rhythm, and in those with sinus rhythm and LVEF ≤35%, these results could not be reproduced in the common multivariable model. For complete results, see Table 2 .
Prognostic Significance in the Matched Sample
The propensity score was derived from 29 baseline variables in a subset of 3016 patients with complete data of these variables. The C-statistic of the propensity score was 0.69. The matching procedure identified 740 pairs of patients with equal probability of either carvedilol or metoprolol succinate therapy while receiving it at equivalent doses. The propensity score matching significantly reduced standardized differences <10% in the absolute values for most observed covariates, demonstrating an improvement in the covariate balance across the treatment groups (Figure 2 ). The distribution of β-blocker dose equivalents in the matched sample is depicted in Table 3 .
In the matched sample, 365 patients died during followup. No significant association between treatment with the 2 β-blockers and all-cause mortality was noted (HR, 1.00; 95% CI, 0.82-1.23; P=0.99). The Kaplan-Meier curve for survival is presented in Figure 3 . The cut offs for age and systolic blood pressure were chosen as they represented the respective cohort median. BPsys indicates systolic blood pressure; CI, confidence interval; eGFR, estimated glomerular filtration rate using the Modification of Diet in Renal Disease equation; HR, hazard ratio; LVEF, left ventricular ejection fraction; and NYHA, New York Heart Association; and OPD, obstructive pulmonary disease. *P <0.05. September 2015
Table 2. Cox Regression Analyses for All-Cause Mortality of the Complete Cohort About Receipt of Metoprolol Succinate (Versus Carvedilol) in the Respective Subgroups Listed, Separate for Adjustment Strategy
Subgroups (Matched Sample)
Survival in carvedilol-treated patients was similar to that of patients receiving metoprolol succinate in all prespecified subgroups in the matched sample. The respective interaction terms indicated absence of significant interaction between subgroups and individual β-blocker agents. The relevant plot is shown in Figure 4 . In addition, the Kaplan-Meier survival curves for matched patients with sinus rhythm and LVEF ≤35% with respect to β-blocker treatment are shown in Figure  I in the Data Supplement.
Bias Reduction, Balance, and Sensitivity Analysis
Our results were supported by the formal sensitivity analysis. The Γ-value was 0.86, indicating only little residual bias (no residual bias at Γ=1.0). Inversely, this means that to attribute a possible survival benefit to an unobserved covariate rather than the receipt of carvedilol or metoprolol succinate, that unobserved covariate would only need to produce a 14% increase in the odds of receipt of a certain β-blocker while being a moderate-to-weak predictor of allcause mortality. We identified N-terminal pro-brain natriuretic peptide, hemoglobin, and loop diuretic dose as variables with a significant amount of missing values ( Table 1) . The multivariable available case model, including N-terminal pro-brain natriuretic peptide, hemoglobin, and loop diuretic dose, comprised n=1239 patients. Its HR was 0.88 (95% CI, 0.66-1.17; P=0. 38) . The multivariable available case model, excluding N-terminal pro-brain natriuretic peptide, hemoglobin, and loop diuretic dose, comprised n=3197 patients. Its HR was 1.06 (95% CI, 0.92-1.23; P=0.42). The multivariable analysis in the multiple imputed data set (n=100 repetitions) yielded an HR of 1.06 (95% CI, 0.94-1.21), which corresponds well to the multivariable available case model, excluding N-terminal pro-brain natriuretic peptide, hemoglobin, and loop diuretic dose.
Following the study by Mitra et al, 28 the calculation of the propensity score was repeated in each of the multiple imputed data sets (n=100), and the propensity score was averaged for each record across the completed data sets. We computed the C-statistic as 0.71 from the logistic regression model with the averaged linear predictor as predictor of caseness and obtained the identical result after averaging over the n=100 C-statistics, computed from each of the imputed samples. This result corroborates the suitability of using the averaged linear predictor in the full original sample for the matching procedure, as proposed by Mitra et al. 28 On the basis of the averaged propensity score of the multiple imputed data sets, the matching procedure identified 939 pairs of patients with equal probability of either carvedilol or metoprolol succinate therapy while receiving it at equivalent doses. Of these, 530 patients died during follow-up. Again, no significant association between β-blocker treatment and 
Discussion
Our results contrast to the findings of COMET, which is the only sufficiently powered prospective clinical trial ever to compare the efficacy of 2 β-blockers in patients with CHF. COMET, in return, was criticized both for its nonequivalent formulation and the inconsistent dosing. As with COMET, more patients on carvedilol in our general cohort received target doses when compared with patients on metoprolol. In this constellation, use of carvedilol was associated with a significant survival benefit, thus reproducing the main result of COMET. This prognostic difference, however, was no longer significant when applying the controlling strategies to the respective Cox models. After matching for both the propensity score and the dose equivalent, the prognostic difference between carvedilol and metoprolol succinate treatment completely disappeared.
It is here that our study significantly adds to the current understanding of guideline-appropriate β-blocker therapy. In real life, target dose may be achieved more frequently when using carvedilol rather than metoprolol, resulting in an indirect survival benefit for patients receiving carvedilol over those receiving metoprolol. An intrinsic prognostic difference between carvedilol and metoprolol succinate, however, seems not to exist when used at equivalent doses.
Our results confirm the notion of an equal prognostic benefit from carvedilol and the succinate formulation of metoprolol, which is brought about both by Wikstrand et al. 21 and Pasternak et al. 29 Although the former compared the published point estimates of the pivotal randomized β-blocker trials, 21 the latter reported data from the Danish Heart Failure Registry. Our study extends their findings both in terms of a significantly longer follow-up duration and the fact that we separately accounted for one of the main criticisms of COMET by introducing dose equivalents into our matching strategy. Furthermore, we could not confirm a dependence of the prognostic benefit derived from either β-blocker on the cause of CHF as noted in a retrospective analysis by Shore et al. 30 Besides the succinate formulation, metoprolol tartrate has also been compared with carvedilol in small prospective trials and retrospective analyses of heart failure databases. [31] [32] [33] [34] [35] The collective findings, however, remained inconclusive. 36, 37 In addition, it has been questioned whether metoprolol tartrate is comparable with metoprolol succinate in the treatment of patients with CHF because data on the comparative effects of the 2 formulations are scarce and again inconclusive. 38, 39 An ongoing meta-analysis on this issue has not yet been published. 40 It seems conceivable, however, that differences in the therapeutic efficiency between carvedilol and metoprolol succinate may exist in certain subgroups of patients. For instance, it has been postulated that carvedilol might induce favorable changes on glycemic control and lipid profiles. [41] [42] [43] [44] In a post hoc analysis of COMET, however, both diabetic and nondiabetic subjects had a similar reduction in mortality with carvedilol when compared with metoprolol tartrate. 43 Also, it was hypothesized that the α-adrenergic properties of carvedilol may offset its nonselective β-blockade-induced bronchoconstriction. 45 This, however, was not confirmed by others. 46 Furthermore, there is conflicting evidence as to the prognostic benefit of β-blockers in patients with CHF and atrial fibrillation. On the one hand, 2 recently published metaanalyses of placebo-controlled randomized β-blocker trials found a lack of efficacy of β-blocker treatment in this patient sample. 47, 48 On the other hand, a retrospective analysis of the US Carvedilol Heart Failure Trial demonstrated that carvedilol improves outcomes in CHF patients with atrial fibrillation. 8 Then again, a retrospective analysis of the MERIT-HF study did not detect an effect of treatment with metoprolol succinate on mortality in the subset of CHF patients with atrial fibrillation. 49 Finally, it has been reported that carvedilol may be preferable to metoprolol tartrate to prevent the development of renal failure in patients with CHF. 50 These studies, however, included few patients, and in some studies follow-up was short. In contrast, we could not demonstrate any inconsistencies in our main result in any of our predefined subgroups in our large cohort with a substantially longer follow-up.
Limitations
A potential limitation to this study is its observational design. However, our data result from comprehensive outpatients' databases with continuous inclusion and close surveillance. These data therefore reflect the effect of carvedilol and metoprolol succinate in real-world patients in contrast to those included in randomized trials. They are clinically relevant to the population of interest as differences between study cohorts and real-world patients are a known phenomenon.
Like any nonrandomized design, propensity matching may not be able to balance unmeasured confounders. A sensitivity analysis cannot prove or rule out the presence of such an unmeasured confounder. In addition, missing values in individual variables may decrease the informative value of the multivariable model or the propensity score. Yet, the results of our sensitivity analysis as well as multivariable available case analyses and multivariable analyses of the multiple imputed data set support our main conclusions. 26 Moreover, the survival analysis in the matched sample, which is based on the multiple imputed data set, reproduced the results of the original analysis. The rigorous testing by 3 different strategies of analysis is an obvious strength of our study. However, we cannot comment on specific reasons for the selection or nonselection of the β-blockers. In addition, our data do not allow identification of patients who either switched from 1 β-blocker to another or changed β-blocker dosing during follow-up. Likewise, we cannot comment on medication adherence. However, inclusion into the analyses of our study was performed after stabilization of both clinical status and medication in an ambulatory setting. This may reduce the necessity for further modulation of β-blocker treatment.
We must further point out that owing to the design of this study, the absence of any association between the use of either carvedilol or metoprolol succinate and all-cause mortality is strictly associative, not causal. We cannot recommend on preferential use of either β-blocker based on this study alone. Also, on a formal basis, the limits of our 95% CI do not rule out the possibility of a 17% lower mortality with carvedilol. However, the symmetrical distribution of the limits around the point estimate of 1.0 lends weight to our interpretation.
Finally, as patients included in our analysis were mainly whites, applying the results obtained from our study to other populations from different ethnic/racial background may not be reliable.
Conclusions
In this retrospective study comparing carvedilol and metoprolol succinate therapy of outpatients with CHF from 2 European HF databases, patients treated with carvedilol were younger and more likely to receive target doses, which entailed improved survival. However, after either multivariable adjustment or matching for propensity and dose equivalence, there was no significant benefit of carvedilol compared with metoprolol succinate for survival.
